Retinal Microenvironment Imbalance in Dry Age-Related Macular Degeneration: A Mini-Review

Brad P. Barnett    James T. Handa
Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Md., USA

Key Words
Aging · Age-related macular degeneration · Complement · Innate immunity · Oxidative stress · Oxidation-specific epitopes

Abstract
Background: Age-related macular degeneration (AMD) is the leading cause of blindness in the western world. To prevent what will certainly be a tremendous health and economic burden, effective therapeutics for AMD are urgently needed. To develop these agents in a timely fashion, the molecular pathways that cause disease progression must be elucidated. Objective: To briefly describe the clinical features of AMD, and review the current understanding of the molecular basis of AMD. Methods: A literature review. Results: The discussion will primarily focus on the interplay of oxidative stress and complement dysregulation and the resulting chronic proinflammatory state thought to be central in AMD pathogenesis. Conclusions: Oxidative stress and complement dysregulation play a substantive role in the development of AMD.

Introduction
Each year millions of individuals lose their central vision, compromising their ability to distinguish faces, read and drive. They will add to the 15–20 million people in the US and more than 50 million worldwide who suffer from age-related macular degeneration (AMD) [1]. Since the principle risk factor for AMD is advanced age, the aging population will increase the health burden from this disease. A better understanding of the pathogenesis of AMD is crucially needed to develop effective therapeutics that prevent or reverse this disease.

The pathogenesis of AMD is influenced by complex crosstalk between various elements of the retinal microenvironment. It is a multifactorial, chronic, age-related disease with both environmental and genetic factors. The past decade has been highly fruitful at elucidating key molecular pathways in AMD. It is clear that oxidative stress resulting from cigarette smoking is strongly linked to AMD. Genetic studies have introduced the role of innate immune dysfunction as a pivotal factor in AMD. In this review, we will describe how oxidative stress and innate immune dysfunction contribute to the development of AMD. We present their roles from the perspective that both pathways are physiological, but with imbalance, they can play a pathological role.

Anatomical and Histological Considerations
The retina has the richest blood supply and greatest oxygen demand by weight of any organ in the body [2]. The retinal microenvironment is inherently pro-oxida-
The health of the overlying photoreceptors, which detect light, is dependent upon diffusion of oxygen and nutrient supply from the richly vascular choroid.

**What Is AMD?**

AMD is a progressive, complex age-related disease. Early disease can go undetected because patients may be without appreciable vision loss [3]. Early ‘dry’ AMD is characterized by whitish-yellow deposits coined drusen that develop in Bruch’s membrane (fig. 2). Drusen can be categorized as either ‘hard’ with distinct margins, or ‘soft’ with indistinct edges [3]. While small hard drusen are typically not associated with disease, soft drusen larger than 125 μm in diameter are pathognomonic for AMD [3]. When large drusen coalesce, they can cause the RPE to separate from Bruch’s membrane, which can lead to RPE apoptosis, and when extensive, result in geographic atrophy, an advanced form of AMD (fig. 2). Accordingly, the risk for advanced AMD is directly re-
lated to the size of drusen and the degree of altered pigmentation in the RPE, which correlates with RPE dysfunction [3].

Advanced AMD can also present as ‘wet’ AMD (fig. 2), involving choroidal neovascularization (CNV), which represents approximately 20% of AMD cases. The aberrant expression of cytokines, such as vascular endothelial growth factor (VEGF), is a central driving factor in the development of the neovascularization. Fortunately, serial intravitreal injections of anti-VEGF antibodies can clinically control the neovascularization [4]. While antioxidant micronutrients can slow vision loss for intermediate AMD, unfortunately, there is no effective therapy for early, dry AMD. The impact of anti-VEGF therapeutics on wet AMD underscores the power of exploiting molecular targets. An understanding of the underlying molecular mechanisms that contribute to early AMD could enable the development of therapeutics for early AMD that prevent vision loss.

Epidemiological Evidence for AMD Risk

A variety of environmental influences have been linked with AMD risk. As the name suggests, advanced age is the strongest risk factor for AMD. Cigarette smoking is the second strongest risk factor, conferring more than twice the risk for developing AMD independent of known genetic risk factors. Tobacco smoke has been shown to be independently associated with AMD in persons with a 10 pack-year smoking history or those exposed to second-hand smoke. Using pooled data from three population-based cohort studies, the relative risk of the late AMD development is 2.4 among current smokers compared to nonsmokers [5]. Cigarette smoke has been shown to increase RPE abnormalities in early disease, and is correlated with geographic atrophy, a late form of AMD characterized by RPE cell death [6].

Cigarette Smoke Is an Exogenous Source of Oxidative Stress

With each puff of cigarette smoke, over 4,700 chemical components including $10^{15}$ free radicals are inhaled. Chemical oxidants in cigarette smoke deplete tissues of ascorbic acid and protein sulphydryl groups, causing the oxidation of DNA, lipids, and proteins [7]. In AMD, many of these oxidative changes result in the formation of malondialdehyde (MDA), 4-hydroxynonenal, carboxymethylpyrrole (CEP), and advanced glycation end-products in the macula. Coupled with basic research indicating an oxidative etiology in AMD [8], such findings support oxidation as a key mechanism in AMD pathogenesis.
Cardinal features of AMD develop in animals exposed to smoke [27]. The RPE of mice exposed to cigarette smoke for 6 months developed an increase in oxidatively damaged DNA, profound loss of basal infoldings, increased intracellular membranous vacuoles, and increased apoptosis compared to the RPE of mice raised in air [27]. These changes are similar to those seen in RPE cells overlying drusen in AMD. A companion study demonstrated increased RPE mitochondrial DNA damage, decreased factor H (CFH) and complement activation with increased C3, C5, and C5b-9 complexes within Bruch’s membrane in smoke-treated mice [28]. Mice given a high-fat diet and smoke developed prominent sub-RPE deposits and Bruch’s membrane thickening [29]. Taken together, a smoke-induced mouse model of AMD is an effective tool for studying AMD pathogenesis as well as validating new therapeutic targets.

### Genetics of AMD

Genetic variants associated with AMD risk [30] include genes that encode proteins involved in oxidative stress and complement pathway modulation (table 1). The single nucleotide polymorphism rs1061170 in CFH, as well as polymorphisms in C2, CFB, C3, and CFI confer a risk for AMD. Genomewide association studies have identified the chromosome 10q26 susceptibility locus

<table>
<thead>
<tr>
<th>Gene</th>
<th>Loci</th>
<th>Function</th>
<th>Odds ratio</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>C2/CFB (complement 2/complement factor B)</td>
<td>6p21</td>
<td>regulator of complement activation</td>
<td>heterozygous = 0.32–0.40</td>
<td>Gold et al. [9]</td>
</tr>
<tr>
<td>C3 (complement 3)</td>
<td>19p13</td>
<td>innate immunity (classical pathway component, alternative complement pathway activator)</td>
<td>homozygous = 1.93–3.91</td>
<td>Yates et al. [10]</td>
</tr>
<tr>
<td>CFH (complement factor H)</td>
<td>1q32</td>
<td>regulator of alternative complement pathway</td>
<td>homozygous = 6.32</td>
<td>Klein et al. [11]; Edwards et al. [12]; Haines et al. [13]; Hageman et al. [14]</td>
</tr>
<tr>
<td>CFHR1/CFHR3 (complement factor H-related 1, 3)</td>
<td>1q31-q32</td>
<td>unknown, possible overlapping function with CFH</td>
<td>heterozygous = 0.29</td>
<td>Spencer et al. [15]</td>
</tr>
<tr>
<td>CFI (complement factor I)</td>
<td>4q25</td>
<td>C3b/C4b inactivator</td>
<td>homozygous = 0.28</td>
<td>Kondo et al. [16]</td>
</tr>
<tr>
<td>CX3CR1 (chemokine [C-X3-C motif], receptor 1)</td>
<td>3p21</td>
<td>inflammation (chemokine receptor)</td>
<td>homozygous = 3.57</td>
<td>Tuo et al. [17]</td>
</tr>
<tr>
<td>ARMS2/LOC387715 (age-related maculopathy susceptibility 2)</td>
<td>10q26</td>
<td>unknown; Localized to mitochondrial outer membrane</td>
<td>homozygous = 8.59</td>
<td>Rivera et al. [18]</td>
</tr>
<tr>
<td>HTRA1 (high temperature requirement A1)</td>
<td>10q26</td>
<td>serine protease</td>
<td>homozygous = 6.92, 7.46</td>
<td>Dewan et al. [19]; Yang et al. [20]</td>
</tr>
<tr>
<td>A4917G</td>
<td>mitDNA</td>
<td>unknown; T haplogroup polymorphism</td>
<td>homozygous = 2.16</td>
<td>Canter et al. [21]</td>
</tr>
<tr>
<td>SOD2 (superoxide dismutase 2)</td>
<td>6q25</td>
<td>mitochondrial matrix enzyme that scavenges oxygen radicals</td>
<td>homozygous = 1.79</td>
<td>Kondo et al. [22]</td>
</tr>
<tr>
<td>ABCA4 (ATP-binding cassette, sub-family A, member 4)</td>
<td>1p22</td>
<td>transport of N-retinylidene-PE across photoreceptor outer segment disc membrane</td>
<td>heterozygous = 5.0</td>
<td>Allikmets [23]</td>
</tr>
<tr>
<td>APOE (apolipoprotein E)</td>
<td>19q13</td>
<td>cholesterol and lipid transport</td>
<td>homozygous = 1.046</td>
<td>Thakkinstian et al. [24]</td>
</tr>
<tr>
<td>CETP (cholesteryl ester transfer protein)</td>
<td>16q21</td>
<td>transfer of cholesteryl esters between lipoproteins</td>
<td>heterozygous = 2.69, 8.21</td>
<td>Rivera et al. [18]</td>
</tr>
<tr>
<td>LPL (lipoprotein lipase)</td>
<td>8p21</td>
<td>hydrolization of triglycerides in lipoproteins</td>
<td>homozygous = 0.82</td>
<td>Neale et al. [25]</td>
</tr>
<tr>
<td>LPC (lipase C)</td>
<td>15q21-q23</td>
<td>hepatic triglyceride lipase</td>
<td>homozygous = 0.39</td>
<td>Yu et al. [26]</td>
</tr>
<tr>
<td>ERCC6 (excision-repair cross-complementing, group 6)</td>
<td>10q11</td>
<td>DNA repair</td>
<td>homozygous = 1.6</td>
<td>Tuo et al. [17]</td>
</tr>
</tbody>
</table>
that contains the rs10490924 variant. Within this region is the LOC387715 gene, which codes for the ARMS2 (age-related maculopathy susceptibility 2) gene, whose function remains an area of active inquiry. Also within this region is the rs11200638 single nucleotide polymorphism which codes for the promoter of HTRA1, a serine protease that is associated with wet AMD [25]. Genome-wide association studies have also uncovered gene variants involved in lipid metabolism such as ABCA1, LIPC, CETP, and LPL.

Genes related to oxidative stress have also been associated with AMD susceptibility (table 1). The mitochondrial DNA polymorphism A4917G, as well as mitochondrial superoxide dismutase 2 (SOD2), confers a risk for AMD. Similarly, the polymorphism in the LOC387715 locus is associated with a higher risk for AMD in smokers than either smoking or the polymorphism alone.

Central Role of RPE and Its Antioxidant System

The RPE plays a central and arguably primary role because RPE dysfunction and atrophy precede the advanced stages of AMD (geographic atrophy and CNV). The literature is replete with examples of the RPE responding to numerous stimuli to orchestrate its own fate and that of the other members of the retinal microenvironment. RNA transcriptome analysis of in vitro RPE cells [32] and human AMD donor eyes [32] have demonstrated a common response to and insults from pathological stressors. Interestingly, significant interindividual variation in RPE transcript expression in AMD donor eyes is seen, further supporting the redundant number of molecular mechanisms leading to an AMD phenotype [33]. In addition, genomewide stress-response transcriptome and proteome assays have begun to elucidate the molecular changes in retina with age, and in response to AMD-associated stresses on whole-genome RPE gene expression [34]. Many RPE-elaborated cytokines released from oxidative stress have been identified in human and experimental AMD specimens [31]. Under physiologic conditions, this robust antioxidant system can neutralize the ROS that result from stressors such as cigarette smoke or light exposure. The generation of ROS has been thought to be a major factor in aging and disease. However, it is clear that ROS participate in a number of physiological processes that are essential to the normal functioning of cells. Redox signaling can act as an important regulatory element in both physiological and pathological processes. Physiological ROS can be generated from several sources [35]. In a pathologic state, in which the balance is tipped and the stressor overwhelms the antioxidant response, ROS persist and can induce the formation of oxidation specific epitopes (OSEs), which will be discussed below.

The macula and in particular, the RPE are protected from oxidative stress through signaling pathways. The most powerful of these transcription systems is the Nrf2 (nuclear factor erythroid-2 related factor 2), a basic leucine zipper transcription factor [31]. Nrf2 regulates a comprehensive, coordinated transcriptional program that maintains cellular redox homeostasis and protects the cell from oxidative injury [31]. Nrf2 is normally sequestered in the cytosol by interacting with Kelch-like ECH-associated protein 1 (Keap1). Keap1 also functions as a substrate adaptor protein for the Cul3-dependent E3 ubiquitin ligase complex, which maintains steady-state levels of Nrf2 via proteolysis by the ubiquitin-proteasome pathway [36]. In the absence of stress, Keap1 constitutively suppresses Nrf2 signaling by degrading Nrf2 and preventing nuclear
Nrf2 translocation, which results in a low baseline expression of antioxidant genes [37]. However, upon exposure to ROS, Keap1 undergoes a conformational change when its multiple cysteine residues interact with ROS, which releases Nrf2 and inhibits Keap1-mediated proteasomal Nrf2 degradation. The released Nrf2 then translocates to the nucleus, where it dimerizes with Maf proteins, and binds to the antioxidant response element (ARE) in the promoters of its target genes to initiate transcription [38].

The Nrf2 signaling response regulates both an early acute phase through actions of the ‘direct’ enzymes, such as catalase or SOD, which neutralize H₂O₂ and superoxide, respectively, a chronic phase through maintenance of cellular glutathione and thioredoxin, and xenobiotic metabolism enzymes that produce reducing equivalents, such as NADPH quinone oxidoreductase (NQO-1) [39]. When ROS depletes cellular glutathione, cells can die from oxidatively mediated apoptosis. Importantly, Nrf2 signaling plays an essential antioxidant role in the RPE [39].

In elderly persons who smoke, Nrf2 signaling is impaired. Suzuki et al. [40] showed that compared with young smokers whose Nrf2 level was independent of smoking status, smoking reduced Nrf2 mRNA in the macrophages of elderly smokers. This study also demonstrated an inverse relation between Nrf2 mRNA levels and oxidized glutathione and carboxylated albumin levels. In pulmonary aspirates from patients with emphysema, Nrf2 signaling is reduced at both the transcription and protein levels, and as a result, antioxidant and glutathione levels are reduced relative to aged-matched controls [40].

Impaired Nrf2 signaling from smoking has been corroborated in animal models. When exposed to tobacco smoke, mice have impaired Nrf2 signaling when measured by changes in Nrf2 and target genes transcription levels in alveolar macrophages [40]. Nrf2 deficient mice exposed to cigarette smoke develop emphysema while wild-type (WT) mice remain unaffected [41]. In these mice, if Keap1 is impaired or Nrf2 is upregulated, the emphysematous changes can be prevented [40].

In the presence of oxidative stress, the innate immune response can be amplified, thereby converting it from a protective to a pathologic response. The Nrf2 signaling system can act to buffer oxidative stress and thus the innate immune response including complement-mediated inflammation. In the lipopolysaccharide (LPS)-induced septic shock model, Nrf2-deficient mice, compared to WT mice, had increased innate immune activity, inflammation, and death [37]. Nrf2 signaling showed a similar protective effect in a model of ocular inflammation [42]. After intraperitoneal LPS injection, the retinas of Nrf2-deficient mice had increased ROS and elevated expression of a number of cytokines compared to WT controls [42]. After LPS challenge, the retinas of WT mice demonstrated increased expression of the Nrf2-responsive antioxidant enzymes (NQO-1 and glutamate-cysteine ligase, modifier subunit) compared to Nrf2-deficient mice [42]. Leukocyte adhesion to the vascular endothelium is a key event that precedes leukocyte invasion into tissue. LPS treatment also increased the number of leukocytes adherent to the retinal vascular endothelium after LPS treatment in Nrf2-deficient and WT mice alike. If pretreated with 2-cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im), a small molecule Nrf2 activator, the retinas of WT mice had increased antioxidant gene expression, reduced inflammatory mediator expression, and reduced leukocyte adherence to retinal vasculature. As expected, CDDO-Im did not confer a similar protective effect in Nrf2-deficient mice.

In addition to acute inflammation, deficient Nrf2 signaling can create a chronic proinflammatory environment, a known susceptibility factor for AMD. Nrf2-deficient mice have a prolonged inflammatory response [43], increased oxidative damage and complement C3 deposition in several organs including the brain [44] compared to WT. Conversely, Nrf2 activation prevents inflammation mediated by oxidative stress. For example, in a model of liver necrosis, Nrf2 activation by triterpenoids prevented late phase proinflammatory gene expression, thereby halting the inflammatory amplification loop [39].

Recently, several features of AMD have been shown in 12-month-old Nrf2-deficient mice that included the accumulation of lipofuscin and membranous vacuoles within the RPE, and drusen-like deposits along with the accumulation of inflammatory proteins in Bruch’s membrane. Taken together, it appears that upregulating the Nrf2 pathway can dually provide direct antioxidant effect and reduce the accompanying pro-inflammatory response during conditions like AMD.

Oxidation-Specific Epitopes Are a Link to Chronic Oxidative Stress and Innate Immune Activation

Inadequately neutralized ROS can cause oxidize lipids, such as the peroxidation of polyunsaturated fatty acids. Resulting lipid hydroperoxides, in the presence of iron and other transition metals, can give rise to esterified and unesterified aldehydes. These lipid peroxidation products can modify proteins, lipids, and DNA. These oxidized self structures have been coined ‘OSEs’ [45]. Unlike ROS,
which are short lived, OSEs can produce a chronic inflammatory nidus if not neutralized or removed. For example, apoptotic bodies are highly enriched with OSEs. These OSEs are thought to act as immunogenic danger-associated molecular pattern molecules, tags that enable the body to identify and clear biological waste. A delicate balance exists between a protective clearance response and pathologic autoinflammatory response to danger-associated molecular pattern molecules/OSEs. In the pathologic state, ROS are inadequately neutralized, thus forming abundant OSEs that overwhelm innate immune clearance. Not surprisingly, OSEs have been identified in numerous diseases in which oxidative stress and inflammation are thought to be key factors, including Alzheimer’s disease, atherosclerosis, diabetes, muscular dystrophy, rheumatoid arthritis, and lupus [45].

OSEs activate the innate immune response through interaction with pattern recognition receptors (PRRs). Each PRR, which is germ line encoded, is capable of binding highly conserved motifs on numerous pathogens, and provides a first-line defense against invading pathogens. In addition to pathogens, PRRs bind self-epitopes such as OSEs. OSEs can be endocytosed after binding to PRRs on natural killer cells, monocytes/macrophages, and dendritic cells. When macrophages, dendritic cells, and other antigen-presenting cells have PRR bound, they can interact with T cells, thereby converting innate to adaptive immunity. When in the fluid phase, PRRs can bind and neutralize OSEs and promote their removal. Under physiologic conditions, phagocytic cells can clear OSEs and other DAMPs without causing collateral damage to the neighboring healthy tissue. In the pathologic state, PRR-mediated signaling cascades can cause elevated cytokine and chemokine release, which induces pathologic inflammation, and in certain instances, autoimmunity.

MDA is an OSE that accumulates in numerous oxidative-stress-related diseases. CFH, traditionally considered a major regulator of the alternative complement pathway, was recently found to be a PRR that specifically binds MDA [8]. In pull down experiments with MDA covered beads, CFH was the predominant protein bound in pooled plasma from mice lacking immunoglobulins. CFH in human plasma also selectively bound MDA. The study demonstrated MDA-CFH specificity because other OSEs including oxidized phosphocholine-BSA, CEP-BSA, and 4-hydroxynonenal-BSA did not bind to CFH to any measurable extent [8].

Of the 20 globular short consensus repeats (SCRs) of CFH [46], only the SCR7 or SCR20 fragments bound MDA. These domains are clustering points of various disease-related mutations including the 402H variant in SCR7 that confers risk for AMD. Plasma from patients with the 402H CFH variant has impaired MDA binding [46]. Irrespective of total plasma CFH levels, MDA binding is further decreased in persons homozygous for the 402H CFH variant compared to heterozygotes. CFH also bound MDA decorated apoptotic debris resulting in the generation of iC3b inactivation fragments. The 402H CFH variant had impaired C3b inactivation when incubated with MDA apoptotic particles. Since iC3b opsonins promote the clearance of apoptotic cells without generating inflammation [47], the 402H CFH variant predisposes to a proinflammatory state during the clearance of apoptotic cells. Thus, during RPE cell apoptosis in early AMD, the risk 402H CFH variant could potentially promote tissue-injuring inflammation while apoptotic RPE debris is being cleared.

CFH blocked the uptake of MDA-modified proteins by macrophages in vitro and prevented IL-8 induction by RPE cells in vitro and in vivo. Mice challenged with intravital injections of MDA had increased IL-8 production in the RPE/choroid, compared to mice receiving injections of MDA first bound and neutralized by CFH. These novel results suggest that therapeutic targets which modulate PRR OSEs such as CFH mimetics may prove useful in treating AMD and other chronic inflammatory diseases.

Another area of active inquiry in the AMD field is the relation of inflammasome activation to AMD development. Inflammasomes are multiprotein complexes composed of three components including the pattern recognition receptor NOD-like receptor family, pyrin domain containing 3 (NLRP3), the adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC), and pro-caspase-1. When activated by DAMPs, inflammatory cells such as macrophages, orchestrate assembly of the inflammasome [48]. The inflammasome may have different influence depending upon the stage of AMD. In a paradigm shifting study, Doyle et al. [48] found that inflammasome-generated inflammation may be protective in AMD. The study demonstrated that drusen isolated from patients with AMD and drusen components complement C1q and the OSE CEP, activate the NLRP3 inflammasome [48]. When immunized with CEP, mice develop AMD-like lesions, including drusen accumulation [49]. In these mice, NLRP3 and caspase-1 were upregulated in the macrophages near drusen [48], suggesting direct inflammasome activation by drusen components. NLRP3 inflammasomes, once activated, increase the conversion of pro-IL-1β and pro-IL-18 into active
IL-1β and IL-18, respectively, as well as activating other inflammatory cytokines [48]. In a laser-induced CNV mouse model of wet AMD, a lack of NLRP3 or IL-18 exacerbated CNV formation [48]. Accordingly, the study supports a protective role of the NLRP3 inflammasome and IL-18 in preventing neovascular AMD. Current efforts in the field are directed towards determining if knocking out other inflammasome components (such as ASC and caspase-1) will similarly worsen CNV. Conversely, others are exploring whether inflammasome activation or increased IL-18 can suppress CNV.

On the other hand, the Ambati lab reported that toxic accumulation of abnormal RNA products in patients and mice deficient in DICER1 can modulate NLRP3 inflammasome and AMD development. They found that inhibiting the inflammasome prevented RPE degeneration and geographic atrophy. They suggested that efforts to control the inflammasome, just as in early infection, may prevent AMD development [50].

### Putting It Together: The Interplay of Metabolic Oxidative Stress and Innate Immune Dysfunction in AMD Pathogenesis

Figure 3 summarizes a proposed mechanism for how metabolic oxidative stress and innate immune hyperactivity play a role in early AMD development. In this model, no component is inherently pathologic or protective. Instead, each has a physiologic role, and in cases of imbalance, a pathologic role. In the physiologic state, low levels of ROS provide oxidant signaling that maintains healthy cellular function. When stressors such as chronic light exposure or cigarette smoking overwhelm the antioxidant system of the retina, ROS become pathological by introducing a cascade of tissue injuring events related to oxidative and inflammatory damage. With decreased Nrf2 signaling seen with aging, inadequately neutralized ROS create OSEs. OSEs activate the innate immune response when they interact with PRRs. Membrane bound PRRs facilitate phagocytosis of OSEs while fluid-phase PRRs may bind and neutralize OSEs by signaling their removal by immune cells. When this system is overwhelmed by an overabundance or chronic exposure of OSEs, the inflammation can convert from a physiologic to pathologic response. In this pathologic state, the combination of inadequately neutralized oxidative stress and inflammation induce both RPE cell injury and death. The photoreceptors, which rely on the RPE for their health, become dysfunctional, resulting in vision loss. Oxidative modification, such as the formation of advanced glycation endproducts, a collection of OSEs, promotes the retention of other OSEs that may prevent their neutralization or clearance by PRRs. These changes can magnify the inflammatory response and the retention of inflammatory debris or cellular remnants that ultimately contribute to drusen formation.
Future Directions

The line between physiologic and pathological ROS and complement activation in the retina remains to be understood. The current understanding of how Nrf2 signaling protects the retina from oxidative stress is also in its infancy. Future efforts aimed at bolstering the cell’s inherent defense mechanisms against oxidative stress, such as enhancing Nrf2 signaling, are attractive therapeutic targets for AMD. Such a strategy is also intended to reduce oxidative stress before it triggers pathologic innate immune activation. In a similar vein, exploiting PRRs that neutralize OSEs could dampen chronic oxidative stress or complement activation. One of the most exciting PRR targets, clinically relevant in AMD, is CFH, which acts to neutralize the ubiquitous OSE MDA. As the PRR OSE story is also still in its infancy, it is likely that other PRR therapeutic targets will be uncovered. Central to these strategies is a sound understanding of how oxidative stress and complement activation trigger AMD. With this knowledge, it is likely that new therapeutics will soon emerge as a much needed treatment for dry AMD.

Acknowledgements

NEI EY14005 (J.T.H.), EY019904 (J.T.H.), Thome Foundation (J.T.H.), Beckman Foundation Initiative for Macular Research, Research to Prevent Blindness Senior Scientist Award (J.T.H.), Unrestricted grant from Research to Prevent Blindness to the Wilmer Eye Institute, NIH P30EY001765 core grant, Robert Bond Welch Professorship (J.T.H.), and a gift from the Merlau family and Aleda Wright.

References


